Held by 2 specialist biotech funds
**Signal Note: Eventide AVGO Initiation** This $16.4M position in semiconductor infrastructure provider Broadcom likely reflects conviction in AI/data center demand tailwinds that benefit biotech operations—particularly genomics sequencing, drug discovery compute, and real-world evidence platforms. While Broadcom lacks direct pharma exposure, the move suggests Eventide's values-based mandate is expanding into enabling technologies critical to biotech productivity and cost reduction, signaling confidence in secular computational trends outpacing near-term biotech sector headwinds.